Lexicon Pharmaceuticals, Inc. (LXRX) Receives Outperform Rating from Wedbush
Other research analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, July 5th. Cowen and Company reiterated a hold rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Needham & Company LLC reiterated a buy rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. BidaskClub cut shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research report on Thursday, August 10th. Finally, ValuEngine upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, June 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $28.75.
Shares of Lexicon Pharmaceuticals (LXRX) traded down 2.41% during midday trading on Thursday, hitting $11.74. 585,828 shares of the stock were exchanged. Lexicon Pharmaceuticals has a 1-year low of $11.62 and a 1-year high of $19.50. The company’s market capitalization is $1.24 billion. The firm has a 50-day moving average of $13.46 and a 200-day moving average of $14.98.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $18.34 million. During the same quarter in the previous year, the business posted ($0.37) earnings per share. Lexicon Pharmaceuticals’s quarterly revenue was down 40.3% on a year-over-year basis. On average, equities analysts expect that Lexicon Pharmaceuticals will post ($1.47) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/lexicon-pharmaceuticals-inc-lxrx-receives-outperform-rating-from-wedbush/1613702.html.
In other news, insider Lonnel Coats acquired 30,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were acquired at an average price of $12.54 per share, for a total transaction of $376,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.77% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of LXRX. USS Investment Management Ltd purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at $57,705,000. Pinnacle Associates Ltd. purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at $11,759,000. Vanguard Group Inc. boosted its stake in shares of Lexicon Pharmaceuticals by 16.3% during the first quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after purchasing an additional 585,222 shares during the period. Highbridge Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at $7,813,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at $5,485,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.